Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies.

ABSTRACT: Model-informed drug discovery is endorsed by the US Food and Drug Administration (FDA) to improve the flow of medicines from bench to bedside. In the case of monoclonal antibodies, this necessitates taking into account not only the pharmacokinetic (PK) properties of the drug, but also the tissue distribution, concentration, and turnover of the target to guide dose and affinity selection, as well as serve as a link to downstream pharmacology. Relevant information (e.g., tissue proteomic data from quantitative mass spectrometry), is increasingly available from public domain data repositories, although not necessarily in the form that is directly usable for the purpose of quantitative, predictive, and mechanistic PK/pharmacodynamic (PD) modeling based on molarity or similar frameworks instead

SUBMITTER: Muliaditan M 

PROVIDER: S-EPMC9283736 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature